{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:25Z","timestamp":1791313645966,"version":"4.3.1"},"reference-count":37,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the efficacy and safety data of children with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with abatacept (ABA) + methotrexate (MTX) or ABA monotherapy when prior MTX use was either ineffective or not tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Posthoc analysis of 2 phase III trials of subcutaneous (SC) and intravenous (IV) ABA over 2 years in patients with pcJIA (aged 2-17 years). Patients were stratified by treatment with ABA + MTX or ABA monotherapy and further by prior biologic use. Efficacy outcomes included JIA\u2013American College of Rheumatology (JIA-ACR) responses, Juvenile Arthritis Disease Activity Score in 27 joints using C-reactive protein (JADAS27-CRP), and safety. Descriptive pharmacokinetic analyses were also performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Efficacy responses (JIA-ACR and JADAS27-CRP) were similar between patients receiving ABA + MTX (n = 310) or ABA monotherapy (n = 99) and persisted over 2 years. Clinical response rates were similar in biologic-na\u00efve patients and prior biologic users; this was independent of MTX use. Across both studies, ABA + MTX and ABA monotherapy displayed similar safety profiles. Pharmacokinetic results revealed similar minimum steady-state trough ABA concentrations between studies. Further, baseline MTX did not influence ABA clearance and was not a significant predictor of JIA-ACR responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ABA monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of ABA appear to be independent of MTX coadministration. Consequently, ABA monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate. (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01844518\">NCT01844518<\/jats:ext-link>and<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00095173\">NCT00095173<\/jats:ext-link>)<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2022-1320","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T12:20:27Z","timestamp":1689423627000},"page":"1471-1480","source":"Crossref","is-referenced-by-count":8,"title":["Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4219","authenticated-orcid":false,"given":"Jordi","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego O.","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lauwerys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Rama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bohnsack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Breedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2775-0111","authenticated-orcid":false,"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Ally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadina","family":"Rubio-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3513-2989","authenticated-orcid":false,"given":"Elisabeth","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riana","family":"Van Zyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Askelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"2023110700351058000_50.11.1471.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"2023110700351058000_50.11.1471.2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2023110700351058000_50.11.1471.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.22473"},{"key":"2023110700351058000_50.11.1471.4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2023110700351058000_50.11.1471.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213030"},{"key":"2023110700351058000_50.11.1471.6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1546-0096-12-51","article-title":"Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review","volume":"12","author":"van Dijkhuizen","year":"2014","journal-title":"Pediatric Rheumatol Online J"},{"key":"2023110700351058000_50.11.1471.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041810"},{"key":"2023110700351058000_50.11.1471.8","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199803)41:3<381::AID-ART2>3.0.CO;2-3"},{"key":"2023110700351058000_50.11.1471.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"key":"2023110700351058000_50.11.1471.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014886"},{"key":"2023110700351058000_50.11.1471.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"2023110700351058000_50.11.1471.12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2023110700351058000_50.11.1471.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"2023110700351058000_50.11.1471.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"2023110700351058000_50.11.1471.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"2023110700351058000_50.11.1471.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"2023110700351058000_50.11.1471.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"2023110700351058000_50.11.1471.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099"},{"key":"2023110700351058000_50.11.1471.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"2023110700351058000_50.11.1471.20","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"2023110700351058000_50.11.1471.21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2352-4642(18)30034-8","article-title":"Current and future perspectives in the management of juvenile idiopathic arthritis","volume":"2","author":"Ruperto","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"2023110700351058000_50.11.1471.22","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023110700351058000_50.11.1471.23","doi-asserted-by":"crossref","unstructured":"Brunner HI , Tzaribachev N , Louw I , ; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) investigators . Long-term maintenance of clinical responses by individual patients with polyarticular-course juvenile idiopathic arthritis treated with abatacept. Arthritis Care Res 2023 May 23 (Epub ahead of print).","DOI":"10.1002\/acr.25156"},{"key":"2023110700351058000_50.11.1471.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540350075038"},{"key":"2023110700351058000_50.11.1471.25","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.188946"},{"key":"2023110700351058000_50.11.1471.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12969-018-0261-x","article-title":"Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology","volume":"16","author":"Brunner","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"2023110700351058000_50.11.1471.27","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2023110700351058000_50.11.1471.28","first-page":"1058","article-title":"Preliminary definition of disease flare in juvenile rheumatoid arthritis","volume":"29","author":"Brunner","year":"2002","journal-title":"J Rheumatol"},{"key":"2023110700351058000_50.11.1471.29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"2023110700351058000_50.11.1471.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"2023110700351058000_50.11.1471.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200237"},{"key":"2023110700351058000_50.11.1471.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.34373"},{"key":"2023110700351058000_50.11.1471.33","first-page":"S1","article-title":"Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology","volume":"19","author":"Ruperto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2023110700351058000_50.11.1471.34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/acr2.11375","article-title":"Analysis of the immunogenicity from abatacept-treated pediatric patients with polyarticular-course juvenile idiopathic arthritis: findings from two phase III clinical trials","volume":"4","author":"Mora","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2023110700351058000_50.11.1471.35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jcph.1308","article-title":"Population pharmacokinetics and exposure-response relationship of intravenous and subcutaneous abatacept in patients with rheumatoid arthritis","volume":"59","author":"Li","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2023110700351058000_50.11.1471.36","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jcph.1797","article-title":"Model-based selection and recommendation for subcutaneous abatacept dose in patients with polyarticular juvenile idiopathic arthritis","volume":"61","author":"Gandhi","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2023110700351058000_50.11.1471.37","doi-asserted-by":"publisher","DOI":"10.1186\/ar2666"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2022-1320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:38:00Z","timestamp":1699346280000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2022-1320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.3899\/jrheum.2022-1320"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2022-1320","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]}}}